FULC Q3 2023 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$436M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$759,000-35.8% YoY

Gross Profit

-$17M-2302.9% margin

Operating Income

-$27M-3615.3% margin

Net Income

-$24M-3164.3% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-13.8%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$279M

Total Liabilities

$23M

Stockholders' Equity

$255M

Cash & Equivalents

$30M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$759,000	$1M	-35.8%
Gross Profit	-$17M	-$14M	-23.2%
Operating Income	-$27M	-$24M	-12.7%
Net Income	-$24M	-$24M	-1.2%